Atossa Genetics: Potential Breakthrough in Breast Cancer?

Biopharmaceutical Company Atossa Genetics Receives Buy Rating from H.C. Wainwright, Sets New Price Target at $4.00

Biopharmaceutical company Atossa Genetics received a Buy rating from H.C. Wainwright on Monday, with a new price target set at $4.00. The company is recognized for its promising pipeline centered around Z-endoxifen, an active metabolite of the drug tamoxifen.